Back to Search Start Over

Predictors of Febrile Neutropenia Among Cancer Patients Receiving Myelosuppressive Chemotherapy in US Clinical Practice

Authors :
Lyman, Gary H.
Richert-Boe, Kathryn
Lamerato, Lois
Kaur, Manpreet
Shah, Neel
Lawrence, Tatiana
Sundaresan, Devi
Silvia, Amanda
Hanau, Ahuva
Weycker, Derek
Source :
Blood; November 2019, Vol. 134 Issue: Supplement 1 p5854-5854, 1p
Publication Year :
2019

Abstract

Lyman: G1 Therapeutics, Halozyme Therapeutics, Partners Healthcare, Hexal, Bristol-Myers Squibb, Helsinn Therapeutics, Amgen Inc., Pfizer, Agendia, Genomic Health, Inc.: Consultancy; Janssen Scientific Affairs, LLC: Research Funding; Amgen Inc.: Other: Research support, Research Funding; Generex Biotechnology: Membership on an entity's Board of Directors or advisory committees. Lamerato:National Cancer Institute, Centers for Disease Control and Prevention, Amgen Inc., AstraZeneca, Evidera, eMAX Health: Research Funding. Kaur:Amgen Inc., Evidera, eMAX Health: Research Funding. Shah:Amgen Inc.: Employment, Equity Ownership. Lawrence:Amgen Inc.: Employment, Equity Ownership. Silvia:Amgen Inc.: Research Funding. Hanau:Amgen Inc.: Research Funding. Weycker:Amgen Inc.: Research Funding.

Details

Language :
English
ISSN :
00064971 and 15280020
Volume :
134
Issue :
Supplement 1
Database :
Supplemental Index
Journal :
Blood
Publication Type :
Periodical
Accession number :
ejs53605174
Full Text :
https://doi.org/10.1182/blood-2019-123524